These in vivo results revealed that hepatic sEVs have a stimulative role in NLRP3 inflammasome-dependent endothelial hyperpermeability in coronary microvessels during NAFLD. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.